Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Virology

• Publication date

  2017-03-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.02059-16PMID 28275196PMCID PMC5411601
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.

  2015influential reference
• CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner

  2015cited by this paper
• Novel antigens for RSV vaccines.

  2015cited by this paper
• A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children

  2015cited by this paper
• Functional Analysis of the 60-Nucleotide Duplication in the Respiratory Syncytial Virus Buenos Aires Strain Attachment Glycoprotein

  2015cited by this paper
• An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice.

  2015cited by this paper
• Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures

  2015cited by this paper
• Role of Fractalkine/CX3CL1 and Its Receptor in the Pathogenesis of Inflammatory and Malignant Diseases with Emphasis on B Cell Malignancies

  2014cited by this paper
• Respiratory syncytial virus: clinical and epidemiological pattern in pediatric patients admitted to a children's hospital between 2000 and 2013.

  2014cited by this paper
• Prophylaxis with a Respiratory Syncytial Virus (RSV) Anti-G Protein Monoclonal Antibody Shifts the Adaptive Immune Response to RSV rA2-line19F Infection from Th2 to Th1 in BALB/c Mice

  2014cited by this paper
• Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection.

  2014cited by this paper
• Respiratory Syncytial Virus G Protein CX3C Motif Impairs Human Airway Epithelial and Immune Cell Responses

  2013cited by this paper
• Neuron–glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage

  2013cited by this paper
• Regulation of Adaptive Immunity by the Fractalkine Receptor during Autoimmune Inflammation

  2013cited by this paper
• A Respiratory Syncytial Virus (RSV) Anti-G Protein F(ab′)2 Monoclonal Antibody Suppresses Mucous Production and Breathing Effort in RSV rA2-line19F-Infected BALB/c Mice

  2013cited by this paper
• Respiratory syncytial virus morbidity, premorbid factors, seasonality, and implications for prophylaxis.

  2012cited by this paper
• Antibodies for prevention and treatment of respiratory syncytial virus infections in children.

  2012cited by this paper
• Fractalkine: a survivor's guide: chemokines as antiapoptotic mediators.

  2012cited by this paper
• Burden of respiratory syncytial virus infection in young children.

  2012cited by this paper
• The Human Respiratory Syncytial Virus Matrix Protein Is Required for Maturation of Viral Filaments

  2012cited by this paper
• CX3CL1 in allergic diseases: not just a chemotactic molecule

  2012cited by this paper
• Conserved cysteine residues within the attachment G glycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responses

  2011cited by this paper
• Differential Pathogenesis of Respiratory Syncytial Virus Clinical Isolates in BALB/c Mice

  2011cited by this paper
• Respiratory Syncytial Virus Glycoprotein G Interacts with DC-SIGN and L-SIGN To Activate ERK1 and ERK2

  2011cited by this paper
• Evidence for a causal relationship between respiratory syncytial virus infection and asthma

  2011cited by this paper
• Biological challenges and technological opportunities for respiratory syncytial virus vaccine development

  2011cited by this paper
• Prophylactic Treatment with a G Glycoprotein Monoclonal Antibody Reduces Pulmonary Inflammation in Respiratory Syncytial Virus (RSV)-Challenged Naïve and Formalin-Inactivated RSV-Immunized BALB/c Mice

  2010cited by this paper
• Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

  2010cited by this paper
• CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung

  2010cited by this paper
• Risk Factors in Children Hospitalized With RSV Bronchiolitis Versus Non–RSV Bronchiolitis

  2010cited by this paper
• Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells.

  2010cited by this paper
• Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice.

  2009cited by this paper
• Respiratory Syncytial Virus Proteins Modulate Suppressors of Cytokine Signaling 1 and 3 and the Type I Interferon Response to Infection by a Toll-Like Receptor Pathway

  2009cited by this paper
• A Chimeric A2 Strain of Respiratory Syncytial Virus (RSV) with the Fusion Protein of RSV Strain Line 19 Exhibits Enhanced Viral Load, Mucus, and Airway Dysfunction

  2009cited by this paper
• Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice.

  2009cited by this paper
• The burden of respiratory syncytial virus infection in young children.

  2009cited by this paper
• Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings 2007

  2008cited by this paper
• Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFN-beta induction.

  2008cited by this paper
• The Secreted Form of Respiratory Syncytial Virus G Glycoprotein Helps the Virus Evade Antibody-Mediated Restriction of Replication by Acting as an Antigen Decoy and through Effects on Fc Receptor-Bearing Leukocytes

  2008cited by this paper
• 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings

  2007cited by this paper
• Respiratory Syncytial Virus G Protein and G Protein CX3C Motif Adversely Affect CX3CR1+ T Cell Responses

  2006cited by this paper
• The Cysteine-Rich Region and Secreted Form of the Attachment G Glycoprotein of Respiratory Syncytial Virus Enhance the Cytotoxic T-Lymphocyte Response despite Lacking Major Histocompatibility Complex Class I-Restricted Epitopes

  2006cited by this paper
• The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin.

  2005cited by this paper
• Respiratory syncytial virus deficient in soluble G protein induced an increased proinflammatory response in human lung epithelial cells.

  2004cited by this paper
• Enhanced Disease and Pulmonary Eosinophilia Associated with Formalin-Inactivated Respiratory Syncytial Virus Vaccination Are Linked to G Glycoprotein CX3C-CX3CR1 Interaction and Expression of Substance P

  2003cited by this paper
• The G Glycoprotein of Respiratory Syncytial Virus Depresses Respiratory Rates through the CX3C Motif and Substance P

  2003cited by this paper
• CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein

  2001cited by this paper
• Immunoregulatory role of secreted glycoprotein G from respiratory syncytial virus.

  2001cited by this paper
• The Attachment (G) Glycoprotein of Respiratory Syncytial Virus Contains a Single Immunodominant Epitope That Elicits Both Th1 and Th2 CD4+ T Cell Responses1

  2000cited by this paper
• Respiratory Syncytial Virus G and/or SH Glycoproteins Modify CC and CXC Chemokine mRNA Expression in the BALB/c Mouse

  2000cited by this paper
• Respiratory Syncytial Virus G and/or SH Protein Alters Th1 Cytokines, Natural Killer Cells, and Neutrophils Responding to Pulmonary Infection in BALB/c Mice

  1999cited by this paper
• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

  1998cited by this paper
• Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.

  1998cited by this paper
• Atypical Pulmonary Eosinophilia Is Mediated by a Specific Amino Acid Sequence of the Attachment (G) Protein of Respiratory Syncytial Virus

  1998cited by this paper
• Eliminating a Region of Respiratory Syncytial Virus Attachment Protein Allows Induction of Protective Immunity without Vaccine-enhanced Lung Eosinophilia

  1998cited by this paper
• Respiratory Syncytial Virus Immune Globulin

  1997cited by this paper
• Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant.

  1997cited by this paper
• Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates.

  1996cited by this paper
• IL‐8 release from human neutrophils by the respiratory syncytial virus is independent of viral replication

  1996cited by this paper
• Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

  1993cited by this paper
• Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children

  1993cited by this paper
• Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies

  1988cited by this paper
• Identification of epitopes on respiratory syncytial virus proteins by competitive binding immunoassay

  1986cited by this paper
• Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay

  1985cited by this paper
• An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.

  1969cited by this paper
• Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.

  1969cited by this paper
• Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

  1969cited by this paper
• Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population.

  1969cited by this paper

• Comparative evaluation of two platforms delivering RSV mRNA vaccines expressing modified extracellular domain of G glycoprotein in mice.

  2026cites this paper
• Genome-Wide Analyses of Human Respiratory Syncytial Viruses Provide Insights into Evolutionary Dynamics

  2025cites this paper
• Quantitative Analysis of Virus Adsorption and Co-adsorption Behavior Using BET Modeling and SERS Spectroscopy

  2025cites this paper
• The role of respiratory syncytial virus G protein in immune cell infection and pathogenesis

  2024cites this paper
• Detection of SARS-CoV-2 in patient specimens by surface enhanced Raman spectroscopy and deep learning

  2024cites this paper
• Rapid Detection of SARS-CoV-2 Variants Using an Angiotensin-Converting Enzyme 2-Based Surface-Enhanced Raman Spectroscopy Sensor Enhanced by CoVari Deep Learning Algorithms

  2024cites this paper
• Immune Responses and Protection Profiles in Mice Induced by Subunit Vaccine Candidates Based on the Extracellular Domain Antigen of Respiratory Syncytial Virus G Protein Combined with Different Adjuvants

  2024cites this paper
• Infection of nonclassic monocytes by respiratory syncytial virus induces an imbalance in the CD4+ T-cell subset response

  2024cites this paper
• Respiratory syncytial virus glycoprotein G impedes CX3CR1-activation by CX3CL1 and monocyte function

  2024cites this paper
• Immunogenicity and protective efficacy of an RSV G S177Q central conserved domain nanoparticle vaccine

  2023cites this paper
• Reshaping Our Knowledge: Advancements in Understanding the Immune Response to Human Respiratory Syncytial Virus

  2023cites this paper
• Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein

  2023cites this paper
• Mutation in the CX3C Motif of G Protein Disrupts Its Interaction with Heparan Sulfate: A Calorimetric, Spectroscopic, and Molecular Docking Study

  2022influential citation
• Ephedrae Herba and Cinnamomi Cortex interactions with G glycoprotein inhibit respiratory syncytial virus infectivity

  2022cites this paper
• RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses

  2022cites this paper
• Rapid and quantitative detection of respiratory viruses using surface-enhanced Raman spectroscopy and machine learning.

  2022cites this paper
• Codon-optimization of the respiratory syncytial virus (RSV) G protein expressed in a vesicular stomatitis virus (VSV) vector improves immune responses in a cotton rat model.

  2022cites this paper
• Neuron‐glia crosstalk in neuronal remodeling and degeneration: Neuronal signals inducing glial cell phagocytic transformation in Drosophila

  2022cites this paper
• Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens

  2022cites this paper
• Ephedrae Herba and Cinnamomi Cortex interactions with G glycoprotein inhibit respiratory syncytial virus infectivity

  2022cites this paper
• Immunopathology of RSV: An Updated Review

  2021cites this paper
• Immunogenicity and inflammatory properties of respiratory syncytial virus attachment G protein in cotton rats

  2021cites this paper
• Respiratory Syncytial Virus (RSV) G Protein Vaccines With Central Conserved Domain Mutations Induce CX3C-CX3CR1 Blocking Antibodies

  2021influential citation
• A metabolism-related gene signature for predicting the prognosis and therapeutic responses in patients with hepatocellular carcinoma

  2021influential citation
• Structural Characterization and Binding Studies of the Ectodomain G Protein of Respiratory Syncytial Virus Reveal the Crucial Role of pH with Possible Implications in Host–Pathogen Interactions

  2021cites this paper
• Functional Features of the Respiratory Syncytial Virus G Protein

  2021cites this paper
• Inhibition of respiratory syncytial virus infectivity by Ephedrae Herba and Cinnamomi Cortex through interaction with G glycoprotein

  2021cites this paper
• Structural Characterization of Ectodomain G Protein of Respiratory Syncytial Virus and Its Interaction with Heparan Sulfate: Multi-Spectroscopic and In Silico Studies Elucidating Host-Pathogen Interactions

  2021cites this paper
• Obtaining and Characterization of the Monoclonal Antibodies Against G-Protein of the Respiratory Syncytial Virus

  2020cites this paper
• Up-to-date role of biologics in the management of respiratory syncytial virus

  2020cites this paper
• In vitro model for the assessment of human immune responses to subunit RSV vaccines

  2020cites this paper
• Emerging small and large molecule therapeutics for respiratory syncytial virus

  2020cites this paper
• Respiratory syncytial virus infection: why does disease severity vary among individuals?

  2020cites this paper
• Contribution of Dendritic Cells in Protective Immunity against Respiratory Syncytial Virus Infection

  2020cites this paper
• Towards a unified classification for human respiratory syncytial virus genotypes

  2020cites this paper
• Two RSV Platforms for G, F, or G+F Proteins VLPs

  2020cites this paper
• Immunological goals for respiratory syncytial virus vaccine development.

  2019cites this paper
• Biophysical and flavonoid-binding studies of the G protein ectodomain of group A human respiratory syncytial virus

  2019cites this paper
• Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity

  2019cites this paper
• Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development

  2019cites this paper
• Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes

  2019cites this paper
• Disease Severity in Respiratory Syncytial Virus Infection: Role of Viral and Host Factors

  2019cites this paper
• Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein

  2019cites this paper
• Viral N6-methyladenosine upregulates replication and pathogenesis of human respiratory syncytial virus

  2019cites this paper
• Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types

  2019cites this paper
• Vaccine containing G protein fragment and recombinant baculovirus expressing M2 protein induces protective immunity to respiratory syncytial virus

  2019cites this paper
• Mutation of Respiratory Syncytial Virus G Protein’s CX3C Motif Attenuates Infection in Cotton Rats and Primary Human Airway Epithelial Cells

  2019influential citation
• Development of Luciferase Immunoprecipitation Systems (LIPS) Assay to Detect IgG Antibodies against Human Respiratory Syncytial Virus G-Glycoprotein

  2019cites this paper
• Virus-Specific Antibody, Viral Load, and Disease Severity in Respiratory Syncytial Virus Infection

  2018cites this paper
• Protective antigenic sites in respiratory syncytial virus G attachment protein outside the central conserved and cysteine noose domains

  2018cites this paper
• RSV Strains and Disease Severity.

  2018cites this paper
• Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles

  2018cites this paper
• Structures of respiratory syncytial virus G antigen bound to broadly neutralizing antibodies

  2018cites this paper
• Polyanionic carbosilane dendrimers against viral infections: Human immunodeficiency Virus Type 1, Herpes Simplex Type 2 and Respiratory Syncytial Virus

  2017cites this paper
• Respiratory Syncytial Virus Vaccine Approaches: a Current Overview

  2017cites this paper
• Distinct patterns of innate immune activation by clinical isolates of respiratory syncytial virus

  2017cites this paper